Compare Bristol-Myers Squibb Co (BMY) vs Burlington Stores Inc (BURL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Burlington Stores Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.65 (market cap $119.91B), while Burlington Stores Inc trades at $344.28 (market cap $21.73B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.5× Burlington Stores Inc's market cap, and Bristol-Myers Squibb Co pays a 4.29% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| BMY | BURL | |
|---|---|---|
Market Cap | $119.91B | $21.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $347.82 |
52-Week Low | $42.60 | $242.43 |
Enterprise Value | $155.85B | $26.85B |
Dividend Yield | 4.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Burlington Stores (BURL) trades at $327.59, showing minimal daily movement with a slight 0.04% decline. The stock maintains strong bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust performance with consistent earnings beats, including Q1 2026 EPS of $2.01 exceeding expectations of $1.80. Revenue growth continues with 2025 reaching $10.63 billion and projected increase to $11.9 billion in 2026.
Outlook remains positive with 94% analyst buy ratings and $364.40 consensus price target representing 11% upside. Key opportunities include margin expansion and store productivity improvements, while risks involve competitive retail pressures and inventory management challenges. The company's strong cash flow generation and debt-to-asset ratio of 19.5% provide financial stability for continued growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
